A virus-like particle-based Epstein-Barr virus vaccine.

Area of Science:

• Virology
• Immunology
• Vaccine Development

Background:

• Epstein-Barr Virus (EBV) is a common human herpesvirus linked to infectious mononucleosis and various cancers.
• Immunocompromised individuals, particularly transplant recipients, face significant morbidity and mortality from EBV infections and associated malignancies.
• Prophylactic EBV vaccination is a potential strategy to mitigate these risks.

Purpose of the Study:

• To engineer a cell line for producing Epstein-Barr Virus-like particles (VLPs).
• To evaluate the immunogenicity and safety of EBV-based VLPs as a vaccine candidate.

Main Methods:

• Engineered a producer cell line with a modified EBV genome, lacking oncogenes but retaining VLP assembly proteins.
• Utilized the endosomal sorting complex required for transport (ESCRT) pathway for VLP assembly and release.
• Assessed VLP uptake by human B cells and subsequent T cell epitope presentation.
• Evaluated humoral and cellular immune responses in vitro and in a preclinical mouse model.

Main Results:

• Successfully engineered a producer cell line for EBV-derived VLPs.
• EBV-based VLPs were efficiently taken up by human B cells and presented viral epitopes.
• VLPs demonstrated high immunogenicity, inducing robust humoral, CD8+, and CD4+ T cell responses.
• Preclinical studies in a murine model confirmed the in vitro findings.

Conclusions:

• EBV-based VLPs are safe and highly immunogenic vaccine candidates.
• These VLPs effectively elicit both humoral and cellular immunity against EBV.
• VLP formulations represent a promising approach for developing a safe and effective polyvalent EBV vaccine.